Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
- MHLW Plans to Ease Rules on Public Knowledge-Based Applications during Re-Examination Period
October 3, 2024
- New Cabinet Might Move the Needle in Off-Year Debate: Industry Exec
October 2, 2024
- Japan’s New PM Eyes Social Security Reform as Cabinet Unveiled
October 2, 2024
- MHLW Council Endorses Early Approval Scheme for Medical Countermeasures
October 2, 2024
- Takamaro Fukuoka Named as New Health Minister
October 1, 2024
- Japan Compiles First Biosimilar Roadmap
October 1, 2024
- Japan Sets Up “Moderate-Risk” Post-Approval Change for Shorter Review
October 1, 2024
- Ex-Health Minister Nemoto to Retire from Politics
October 1, 2024
- Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
- MHLW Set to Redefine “Vaccines of High Development Priority” in New Plan
September 27, 2024
- MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025
September 27, 2024
- Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
- Off-Year Debate “Won’t Progress” without Industry’s Behavioral Change: JMA Rep
September 26, 2024
- MHLW Panel Puts a Hold on Proposed Use of Abortion Pill at Clinics Without Beds
September 26, 2024
- Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
- NIBIOHN, Institut Pasteur Link Arms in Drug, Vaccine Research
September 24, 2024
- More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution
September 24, 2024
- Ultragenyx’s Gene Therapy in Line for Orphan Tag in Japan
September 24, 2024
- Orphan Status Granted to Sanofi’s Venglustat and More in Japan
September 24, 2024
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…